CJC-1295 / Ipamorelin Blend

Molecular Profile

Type

Peptide blend

Components

Mechanism & Target Class

Combines two structurally distinct synthetic peptides. CJC-1295 / Mod GRF 1-29 is a 29-residue analog corresponding to the GRF(1-29) sequence with four substitutions (a D-amino-acid residue at position 2 plus substitutions at positions 8, 15, and 27) that confer protease resistance; in its long-circulating form a maleimido-linked side chain forms a covalent bond with serum albumin, extending plasma residence. Ipamorelin is a five-residue C-terminally amidated pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) whose non-proteinogenic residues confer metabolic stability. The two molecules engage separate G-protein-coupled receptor classes (class B and class A GPCRs) as structural binding contexts, so no single molecular target describes the pair.

Storage & Handling

Lyophilized

-20°C; typically stable 24-36 months desiccated and protected from light.

Handling

Avoid freeze-thaw; aliquot; protect from light and moisture.

References (20)

1. Reviews

   1

   Bowers CY. (1998). Compr Physiol

   DOI: 10.1002/j.2040-4603.1998.tb01540.x

2. 2

   Halmos G, Szabo Z, Dobos N, Juhasz E, Schally AV. (2025). Rev Endocr Metab Disord

   DOI: 10.1007/s11154-025-09952-xPubMed 39934495

3. 3

   Laviano A, Molfino A, Rianda S, Rossi Fanelli F. (2012). Curr Pharm Des

   DOI: 10.2174/138161212803216906PubMed 22632856

4. 4

   Mayo KE, Miller T, DeAlmeida V, Godfrey P, Zheng J, Cunha SR. (2000). Recent Prog Horm Res

   PubMed 11036940

5. 5

   Ghigo E, Arvat E, Muccioli G, Camanni F. (1997). Eur J Endocrinol

   DOI: 10.1530/eje.0.1360445PubMed 9186261

6. Clinical

   6

   Beck DE, Sweeney WB, McCarter MD, et al. (2014). Int J Colorectal Dis

   DOI: 10.1007/s00384-014-2030-8NCT00672074

7. 7

   Ionescu M, Frohman LA. (2006). J Clin Endocrinol Metab

   DOI: 10.1210/jc.2006-1702PubMed 17018654

8. 8

   Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. (2006). J Clin Endocrinol Metab

   DOI: 10.1210/jc.2005-1536PubMed 16352683

9. 9

   Gobburu JVS, Agersø H, Jusko WJ, Ynddal L. (1999). Pharm Res

   DOI: 10.1023/A:1018955126402PubMed 10496658

10. 10

    Pandya N, DeMott-Friberg R, Bowers CY, Barkan AL, Jaffe CA. (1998). J Clin Endocrinol Metab

    DOI: 10.1210/jcem.83.4.4711

11. 11

    Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. (1990). J Clin Endocrinol Metab

    DOI: 10.1210/jcem-70-4-975PubMed 2108187

12. 12

    Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. (2009). Growth Horm IGF Res

    DOI: 10.1016/j.ghir.2009.03.001PubMed 19386527

13. Primary research

    13

    Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. (2006). Am J Physiol Endocrinol Metab

    DOI: 10.1152/ajpendo.00201.2006PubMed 16822960

14. 14

    Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. (2005). Endocrinology

    DOI: 10.1210/en.2004-1286PubMed 15817669

15. 15

    Svensson J, Lall S, Dickson SL, Bengtsson BÅ, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson JO. (2000). J Endocrinol

    PubMed 10828840

16. 16

    Johansen PB, Nowak J, Skjærbæk C, Flyvbjerg A, Andreassen TT, Wilken M, Ørskov H. (1999). Growth Horm IGF Res

    PubMed 10373343

17. 17

    Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. (1998). Eur J Endocrinol

    DOI: 10.1530/eje.0.1390552PubMed 9849822

18. 18

    Renner U, Brockmeier S, Strasburger CJ, et al. (1994). J Clin Endocrinol Metab

    DOI: 10.1210/jcem.78.5.8175966PubMed 8175966

19. 19

    Jiménez-Reina L, Cañete R, de la Torre MJ, Bernal G. (2002). Histol Histopathol

    PubMed 12168778

20. 20

    Andersen NB, Malmlöf K, Johansen PB, et al. (2001). Growth Horm IGF Res

    DOI: 10.1054/ghir.2001.0239PubMed 11735244